The RON tyrosine kinase receptor regulates vascular endothelial growth factor production in pancreatic cancer cells

Pancreas

Volumn 39, Issue 3, 2010, Pages 301-307

  Thomas, Ryan M ^a   Jaquish, Dawn V ^b   French, Randall P ^b   Lowy, Andrew M ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Pancreatic cancer; RON; VEGF

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; RECEPTEUR D ORIGINE NANTAIS TYROSINE KINASE RECEPTOR; SCATTER FACTOR; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CANCER CELL; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROTUBULE; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; VASCULAR ENDOTHELIUM;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; HUMANS; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR PROTEIN-TYROSINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77950285105     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181bb9f73     Document Type: Article

References (45)

1. Reinmuth N, Parikh AA, Ahmad SA, et al. Biology of angiogenesis in tumors of the gastrointestinal tract. Microsc Res Tech. 2003;60: 199-207.
2. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell. 1994;79:185-188.
3. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990;82:4-6.
4. Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasisVcorrelation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8.
5. Lee JC, Chow NH, Wang ST, et al. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer. 2000;36:748-753.
6. Takahashi Y, Kitadai Y, Bucana CD, et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995;55:3964-3968.
7. Takahashi Y, Cleary KR, Mai M, et al. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin Cancer Res. 1996;2:1679-1684.
8. Maeda K, Chung YS, Ogawa Y, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer. 1996;77:858-863.
9. Buchler P, Reber HA, Buchler MW, et al. VEGF-RII influences the prognosis of pancreatic cancer. Ann Surg. 2002;236:738-749; discussion 749.
10. Itakura J, Ishiwata T, Friess H, et al. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res. 1997;3:1309-1316.
11. Seo Y, Baba H, Fukuda T, et al. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer. 2000;88:2239-2245.
12. Fong GH. Mechanisms of adaptive angiogenesis to tissue hypoxia. Angiogenesis. 2008;11:121-140.
13. Carmeliet P, Dor Y, Herbert JM, et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 1998;394:485-490.
14. Akagi Y, Liu W, Zebrowski B, et al. Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. Cancer Res. 1998;58:4008-4014.
15. Wang D, Huang HJ, Kazlauskas A, et al. Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. Cancer Res. 1999;59:1464-1472.
16. Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol. 1997;151:1523-1530.
17. Maity A, Pore N, Lee J, et al. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3¶-kinase and distinct from that induced by hypoxia. Cancer Res. 2000;60:5879-5886.
18. Miele C, Rochford JJ, Filippa N, et al. Insulin and insulin-like growth factor-I induce vascular endothelial growth factor mRNA expression via different signaling pathways. J Biol Chem. 2000;275:21695-21702.
19. Worden B, Yang XP, Lee TL, et al. Hepatocyte growth factor/scatter factor differentially regulates expression of proangiogenic factors through egr-1 in head and neck squamous cell carcinoma. Cancer Res. 2005;65:7071-7080.
20. Toyoda M, Takayama H, Horiguchi N, et al. Overexpression of hepatocyte growth factor/scatter factor promotes vascularization and granulation tissue formation in vivo. FEBS Lett. 2001;509:95-100.
21. Dong G, Chen Z, Li ZY, et al. Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res. 2001;61:5911-5918.
22. Thomas RM, Toney K, Fenoglio-Preiser C, et al. The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Res. 2007;67:6075-6082.
23. Camp ER, Yang A, Gray MJ, et al. Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target. Cancer. 2007;109:1030-1039.
24. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801-1806.
25. American Cancer Society. Cancer Facts and Figures 2009. Atlanta: American Cancer Society; 2009.
26. Ronsin C, Muscatelli F, Mattei MG, et al. A novel putative receptor protein tyrosine kinase of the met family. Oncogene. 1993;8:1195-1202.
27. Wang MH, Ronsin C, Gesnel MC, et al. Identification of the RON gene product as the receptor for the human macrophage stimulating protein. Science. 1994;266:117-119.
28. Gaudino G, Follenzi A, Naldini L, et al. RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. EMBO J. 1994;13:3524-3532.
29. Carafoli F, Chirgadze DY, Blundell TL, et al. Crystal structure of the beta-chain of human hepatocyte growth factor-like/macrophage stimulating protein. FEBS J. 2005;272:5799-5807.
30. Iwama A, Yamaguchi N, Suda T. STK/RON receptor tyrosine kinase mediates both apoptotic and growth signals via the multifunctional docking site conserved among the HGF receptor family. EMBO J. 1996;15:5866-5875.
31. Peace BE, Hughes MJ, Degen SJ, et al. Point mutations and overexpression of RON induce transformation, tumor formation, and metastasis. Oncogene. 2001;20:6142-6151.
32. Wang MH, Dlugosz AA, Sun Y, et al. Macrophage-stimulating protein induces proliferation and migration of murine keratinocytes. Exp Cell Res. 1996;226:39-46.
33. Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005;7:469-483.
34. Donovan D, Brown NJ, Bishop ET, et al. Comparison of three in vitro human 'angiogenesis' assays with capillaries formed in vivo. Angiogenesis. 2001;4:113-121.
35. Zhou Q, Kiosses WB, Liu J, et al. Tumor endothelial cell tube formation model for determining anti-angiogenic activity of a tRNA synthetase cytokine. Methods. 2008;44:190-195.
36. Fukuda R, Hirota K, Fan F, et al. Insulin-like growth factor 1 induces hypoxia-inducible factor 1Ymediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem. 2002;277:38205-38211.
37. Saif MW. Pancreatic cancer: is this bleak landscape finally changing? Highlights from the 43rd ASCO annual meeting. Chicago, IL, USA. June 1-5, 2007. JOP. 2007;8:365-373.
38. Lim KH, Baines AT, Fiordalisi JJ, et al. Activation of RalA is critical for ras-induced tumorigenesis of human cells. Cancer Cell. 2005;7:533-545.
39. Yeh JJ, Routh ED, Rubinas T, et al. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. Mol Cancer Ther. 2009;8:834-843.
40. Yip-Schneider MT, Lin A, Marshall MS. Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2. Biochem Biophys Res Commun. 2001;280:992-997.
41. Sengupta S, Gherardi E, Sellers LA, et al. Hepatocyte growth factor/scatter factor can induce angiogenesis independently of vascular endothelial growth factor. Arterioscler Thromb Vasc Biol. 2003;23:69-75.
42. Ho QT, Kuo CJ. Vascular endothelial growth factor: Biology and therapeutic applications. Int J Biochem Cell Biol. 2007;39:1349-1357.
43. Matsuo Y, Ochi N, Sawai H, et al. CXCL8/IL-8 and CXCL12/SDF-1alpha co-operatively promote invasiveness and angiogenesis in pancreatic cancer. Int J Cancer. 2009;124:853-861.
44. Saif MW. Anti-angiogenesis therapy in pancreatic carcinoma. JOP. 2006;7:163-173.
45. Saif MW. New developments in the treatment of pancreatic cancer. Highlights from the 44th ASCO annual meeting. Chicago, IL, USA. May 30YJune 3, 2008. JOP. 2008;9:391-397.